The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APRE | -64.88% | -99.72% | -69.05% | -88% |
| S&P | +14.84% | +96.04% | +14.41% | +65% |
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.12M | -79.0% |
| Gross Profit | $0.11M | -79.7% |
| Gross Margin | 95.40% | -3.7% |
| Market Cap | $9.35M | -57.7% |
| Market Cap / Employee | $1.17M | 0.0% |
| Employees | 8 | 14.3% |
| Net Income | -$3.24M | 6.7% |
| EBITDA | -$3.38M | 12.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $16.53M | -42.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.59% | -14.5% |
| Return On Invested Capital | -140.61% | -8.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.48M | 1.8% |
| Operating Free Cash Flow | -$3.48M | 1.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.58 | 0.81 | 0.58 | 0.60 | -21.59% |
| Price to Sales | 12.46 | 13.04 | 9.52 | 12.22 | -35.47% |
| Price to Tangible Book Value | 0.58 | 0.81 | 0.58 | 0.60 | -21.59% |
| Enterprise Value to EBITDA | 2.10 | 0.60 | 1.41 | 1.63 | 94.92% |
| Return on Equity | -60.2% | -66.7% | -59.8% | -67.5% | 34.79% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
